Halozyme recently acquired two companies producing these other hyper-concentrated biological compounds, Elektrofi for $900M and Surf Bio for $400M. Both of those are admittedly a bit further along in biological drug substances than Nanoform and are starting Phase 1 trials in the coming years.
“For now, Elektrofi’s tech is more advanced, as Halozyme expects two Hypercon-backed client products to begin phase 1 trials this year, with potential approvals in the 2030-to-2031 timeframe. The Surf technology is expected to enter the clinic by the end of 2027 or early 2028.”
According to management comments, converting Nanoform’s biologics line to GMP level would take an estimated 2 years. This news likely points to the party that will pay for that line conversion.